This review synthesizes recent advances (2020-2025) in stem cell-based regenerative medicine, focusing on integrating mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and biomaterials to overcome key translational barriers: poor engraftment (<20% in vivo), immunogenicity, and scalability. While Phase II trials demonstrate iPSC-biomaterial constructs achieving 80-90% differentiation efficiency in cartilage and cardiac repair outperforming embryonic stem cells (ESCs) persistent challenges include tumorigenicity, manufacturing variability, and regulatory hurdles. Most importantly, there are contradictions: MSCs are particularly effective in immunomodulation although with mixed results, and 3D bioprinting improves vascularization but falls behind with organoids on clinical scale. Existing gaps in long-term safety data are exemplified, and a model is suggested to enable the prioritisation of selected strategies of autologous iPSC use in terms of ethical limitations, advancing the field past the existing reviews into the realms of the viable application of the strategy to the clinic.
Trivedi et al. (Wed,) studied this question.